6:12 PM
 | 
Dec 10, 2012
 |  BC Extra  |  Clinical News

Celldex gains on breast cancer subgroup survival data

Celldex Therapeutics Inc. (NASDAQ:CLDX) gained $1.41 (26%) to $6.93 on Monday after reporting final survival data from the 122-patient Phase IIb EMERGE trial of its glembatumumab vedotin ( CDX-011) to treat advanced, refractory or resistant glycoprotein NMB ( GPNMB)-expressing breast cancer....

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >